Ionis Pharmaceuticals - Articles and news items

syndrome

Akcea and Ionis’ familial chylomicronaemia syndrome study a success

Industry news / 23 March 2017 / Niamh Marriott, Junior Editor

Akcea Therapeutics’ pivotal Phase 3 study of volanesorsen reduced triglyceride levels in patients with familial chylomicronaemia syndrome…

Cardiovascular risk

Novartis invests in Ionis’ therapies to reduce cardiovascular risk

Industry news / 10 January 2017 / Niamh Marriott, Digital Editor

Novartis announced a collaboration and option agreement to license two novel treatments with the potential to significantly reduce cardiovascular risk…

GSK initiates Phase 1 study of IONIS-HBV-LRx; Ionis gets milestone payment

Industry news / 13 January 2016 / Victoria White

IONIS-HBV-LRx (previously referred to as ISIS-GSK6-LRx) is a drug Ionis is developing with GSK for the treatment of patients with hepatitis B virus…

FDA grants Orphan Drug Designation to IONIS-HTTRx

Industry news / 5 January 2016 / Victoria White

IONIS-HTTRx is a Gen. 2.0+ antisense drug in development for the treatment of Huntington’s disease…

Isis Pharmaceuticals becomes Ionis Pharmaceuticals

Industry news / 18 December 2015 / Victoria White

Explaining his reasoning behind the company name change, Stanley Crooke, CEO of Ionis, told Forbes: “My underlying concern was that the name was a distraction”…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+